fbpx

Thyroid Eye Disease

The clinical trial we are recruiting for is a Phase 1b, randomized, double-masked, placebo-controlled, multiple ascending dose study evaluating the safety, tolerability, pharmacokinetics, and clinical efficacy of VB421 in subjects with thyroid eye disease (TED).

Click for details.

Register your interest